TACE联合PMCT治疗原发性肝癌的临床观察

目的探讨肝动脉化疗栓塞(TACE)联合经皮微波凝固(PMCT)治疗原发性肝癌的临床疗效。方法选取86例原发性肝癌患者按照数字随机法分为观察组和对照组各43例,观察组采用TACE联合PMCT治疗,对照组采用单纯TACE治疗。观察两组患者治疗后3个月的影像学评价及治疗后1、2、3年的生存率。结果观察组的缓解率为81.40%,明显高于对照组的69.77%,两组比较,差异有统计学意义(P0.05);观察组治疗后1、2、3年的生存率分别为86.49%、72.06%、60.82%,均明显高于对照组的69.14%、53.37%、36.25%,两组比较,差异有统计学意义(P0.05)。结论 TACE联合PMCT治疗原发性肝癌患者临床疗效显著,不良反应少且有效提高患者的生存率,值得临床推广使用。

Clinical observation of TACE combined with PMCT for primary liver cancer

Objective To investigate the effects of hepatic arterial chemo embolization（ conventional）in combination with percutaneous microwave coagulation therapy（ PMCT） in the treatment of primary liver cancer. Method 86 cases of primary liver cancer admitted in our hospital from February 2010 to June 2013 were enrolled and randomly divided into observation group（ TACE plus PMCT） and control group（ TACE alone）,43 cases for each. The imaging evaluation was performed 3 months after treatment,and 1,2,3 year survival rates were calculated. Results The remission rate of observation group was 81. 40%,significantly higher than that of the control group（ 69. 77%）（ P 〈 0. 05）. The 1,2,and 3 year survival rate after treatment in the observation group were 86. 49%,72. 06% and 60. 82%,respectively,significantly higher than those of control group（ 69. 14%,53. 37%,36. 25%）（ P 〈 0. 05）. Conclusion TACE combined with PMCT for primary liver cancer has the advantages of good effect,little adverse reaction and long survival,worth clinical promotion.